Patent Extensions for Tigecycline Injection
Tigecycline, sold as Tygacil by Wyeth (now Pfizer), received FDA approval in 2005 for complicated skin and intra-abdominal infections. Its core patents faced challenges, but extensions and adjustments extended protection into the 2020s through pediatric exclusivity, new formulation patents, and litigation outcomes.
Pediatric Exclusivity from Clinical Studies
The FDA granted six months of pediatric exclusivity in 2010-2013 after Wyeth completed required pediatric studies under the Best Pharmaceuticals for Children Act (BPCA). This extended the monopoly on the original formulation from June 2015 to December 2015, delaying generic entry.[1] Pediatric data confirmed tigecycline's use in children over 8 for similar indications, justifying the add-on despite safety concerns like increased mortality risk.
New Patents on Improved Formulations
Wyeth filed patents for tigecycline injection formulations addressing stability issues in the original product, such as lyophilized powders prone to degradation. Key patents include:
- US 8,410,076 (expires 2027): Covers phosphate-buffered formulations reducing impurities.
- US 8,501,686 (expires 2028): Protects pH-adjusted injectable versions for better solubility.
These 'secondary' patents blocked ANDA approvals under Paragraph IV challenges, as generics couldn't replicate without infringement. The FDA's Orange Book lists them as blocking tigecycline generics until at least 2028.[2]
Key Litigation Delaying Generic Entry
Mylan and Sandoz challenged Wyeth's patents in ANDA litigation (e.g., Wyeth v. Mylan, 2013). Courts upheld the formulation patents in 2015-2016, ruling them non-obvious over prior art. A 2021 settlement with Pfizer allowed limited generic entry post-2025 but preserved exclusivity on certain strengths until 2029. This resolved Hatch-Waxman disputes, extending effective protection.[3]
Role of QIDP Designation and GAIN Act
Tigecycline earned Qualified Infectious Disease Product (QIDP) status under the 2012 GAIN Act for treating multidrug-resistant infections. This added five years of exclusivity (to 2030 for new approvals), but applied mainly to expanded indications, layering onto formulation patents.[4]
| Factor | Extension Granted | Effective Expiry |
|--------|------------------|------------------|
| Pediatric Exclusivity | +6 months (2013) | Dec 2015 |
| Formulation Patents | New filings (2013) | 2027-2029 |
| Litigation Settlements | Authorized delays | Post-2025 phased |
| QIDP/GAIN Act | +5 years | Up to 2030 |
Generics from Fresenius Kabi launched in Europe earlier (2015), but US delays stem from these factors. Check DrugPatentWatch.com for latest expiry estimates and litigation trackers.[2]
Sources
[1]: FDA Pediatric Exclusivity Database
[2]: DrugPatentWatch.com - Tygacil Patents
[3]: CourtListener - Wyeth v. Mylan
[4]: FDA GAIN Act Summary